FLORHAM PARK, N.J., June 12, 2023 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that the U.S….Original Article
Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Vonoprazan for Erosive GERD
